Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Burcu Aslan

Showing results (21-30 of 38) with videos related to

Pageof 4
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 16, 2020
AMG-176, an Mcl-1 Antagonist, Shows Preclinical Efficacy in Chronic Lymphocytic LeukemiaXue Yi, Aloke Sarkar, Gorkem Kismali, et al.
Blood Cancer Journal|October 28, 2025
Pharmacological profiling in CLL patients during pirtobrutinib therapy and disease progressionShady I Tantawy, Burcu Aslan, Ganiraju Manyam, et al.
Blood Advances|August 23, 2021
Development and characterization of prototypes for in vitro and in vivo mouse models of ibrutinib-resistant CLLBurcu Aslan, Gorkem Kismali, Lisa S Chen, et al.
Molecular Therapy. Nucleic Acids|February 22, 2021
ncRNA therapy with miRNA-22-3p suppresses the growth of triple-negative breast cancerAysegul Gorur, Recep Bayraktar, Cristina Ivan, et al.
Cancer Research|October 16, 2016
Ubiquitous Release of Exosomal Tumor Suppressor miR-6126 from Ovarian Cancer CellsPinar Kanlikilicer, Mohammed H Rashed, Recep Bayraktar, et al.
Journal of Clinical Medicine|March 14, 2026
Real-World Outcomes of Ruxolitinib as Salvage Therapy in Steroid-Refractory Acute and Chronic Graft-Versus-Host Disease: A Multicenter Retrospective Observational Study from TurkeyMehmet Bakırtaş, İlhami Berber, İpek Yönal Hindilerden, et al.
Ebiomedicine|January 19, 2019
PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axisCristian Rodriguez-Aguayo, Emine Bayraktar, Cristina Ivan, et al.
Ebiomedicine|August 1, 2022
Corrigendum to "PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis" [EBioMedicine 40 (2019) 290-304]Cristian Rodriguez-Aguayo, Emine Bayraktar, Cristina Ivan, et al.
Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis|June 24, 2025
The effect of threosulfan-based versus busulfan-based preparation regimens on transplant outcomesBurcu Aslan Candir, Nazik Okumus, Ipek Yonal Hindilerden, et al.
Oncotarget|April 21, 2017
Exosomal miR-940 maintains SRC-mediated oncogenic activity in cancer cells: a possible role for exosomal disposal of tumor suppressor miRNAsMohammed H Rashed, Pinar Kanlikilicer, Cristian Rodriguez-Aguayo, et al.
Pageof 4

Showing results (21-30 of 38) with videos related to

Sort By:
Pageof 4
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 16, 2020
AMG-176, an Mcl-1 Antagonist, Shows Preclinical Efficacy in Chronic Lymphocytic LeukemiaXue Yi, Aloke Sarkar, Gorkem Kismali, et al.
Blood Cancer Journal|October 28, 2025
Pharmacological profiling in CLL patients during pirtobrutinib therapy and disease progressionShady I Tantawy, Burcu Aslan, Ganiraju Manyam, et al.
Blood Advances|August 23, 2021
Development and characterization of prototypes for in vitro and in vivo mouse models of ibrutinib-resistant CLLBurcu Aslan, Gorkem Kismali, Lisa S Chen, et al.
Molecular Therapy. Nucleic Acids|February 22, 2021
ncRNA therapy with miRNA-22-3p suppresses the growth of triple-negative breast cancerAysegul Gorur, Recep Bayraktar, Cristina Ivan, et al.
Cancer Research|October 16, 2016
Ubiquitous Release of Exosomal Tumor Suppressor miR-6126 from Ovarian Cancer CellsPinar Kanlikilicer, Mohammed H Rashed, Recep Bayraktar, et al.
Journal of Clinical Medicine|March 14, 2026
Real-World Outcomes of Ruxolitinib as Salvage Therapy in Steroid-Refractory Acute and Chronic Graft-Versus-Host Disease: A Multicenter Retrospective Observational Study from TurkeyMehmet Bakırtaş, İlhami Berber, İpek Yönal Hindilerden, et al.
Ebiomedicine|January 19, 2019
PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axisCristian Rodriguez-Aguayo, Emine Bayraktar, Cristina Ivan, et al.
Ebiomedicine|August 1, 2022
Corrigendum to "PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis" [EBioMedicine 40 (2019) 290-304]Cristian Rodriguez-Aguayo, Emine Bayraktar, Cristina Ivan, et al.
Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis|June 24, 2025
The effect of threosulfan-based versus busulfan-based preparation regimens on transplant outcomesBurcu Aslan Candir, Nazik Okumus, Ipek Yonal Hindilerden, et al.
Oncotarget|April 21, 2017
Exosomal miR-940 maintains SRC-mediated oncogenic activity in cancer cells: a possible role for exosomal disposal of tumor suppressor miRNAsMohammed H Rashed, Pinar Kanlikilicer, Cristian Rodriguez-Aguayo, et al.
Pageof 4